• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon R, Heuckmann JM, George J, Ansén S, Sos ML, Soltermann A, Peifer M, Wolf J, Büttner R, Thomas RK

Journal: Clinical Cancer Research
published: 2017 Sep 15

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress